Valuation : Immunic, Inc.

Market Cap 179M 154M 145M 132M 247M 16.92B 248M 1.72B 663M 8.66B 672M 657M 27.6B P/E 2026 *
-3.64x
P/E 2027 * -5.37x
Enterprise Value -101M -86.88M -81.71M -74.59M -140M -9.55B -140M -969M -374M -4.89B -379M -371M -15.58B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.03%
Yield 2026 *
-
Yield 2027 * -
1 day+2.74%
1 week-17.03%
Current month-17.03%
1 month-8.32%
3 months+2.66%
6 months+6.59%
Current year+145.64%
1 week 11.56
Extreme 11.56
15.22
1 month 11.56
Extreme 11.56
17.43
Current year 5.37
Extreme 5.372
17.43
1 year 5.06
Extreme 5.062
17.43
3 years 5.06
Extreme 5.062
21.1
5 years 5.06
Extreme 5.062
145
10 years 5.06
Extreme 5.062
289.9
Manager TitleAgeSince
Chief Executive Officer 48 2026-05-31
Director of Finance/CFO 58 2020-04-16
President 49 2024-07-11
Director TitleAgeSince
Director/Board Member 59 2019-03-31
Chairman 55 2018-12-31
Director/Board Member 64 2019-11-18
Date Insider Type Main position Quantity % Market Cap. Importance
8/6/26 Free

Director

50,740 0.3725%
7/5/26 Free

Director

25,370 0.1862%
7/5/26 Free

Director

25,370 0.1862%
Change 5-day change 1-year change 3-year change Capi.($)
+2.74%-17.03%+72.27%-18.06% 179M
-0.38%-0.99%+42.69%+100.85% 67.98B
-2.71%-0.71%+35.89%+81.43% 64.94B
-0.31%+3.67%-12.96%+374.95% 27.58B
+0.86%+2.12%-7.74%-13.34% 26.06B
-0.58%-2.55%+23.70%+12.93% 25.74B
-1.11%+0.90%+22.24%-18.50% 20.09B
+1.15%-5.02%+219.82%+379.02% 17.16B
-1.59%-1.43%-8.30%+518.18% 14.92B
-0.20%+8.00%+55.78%+167.98% 14.62B
Average -0.20%-0.60%+44.34%+158.54% 27.93B
Weighted average by Cap. -0.82%+0.46%+36.55%+138.88%

Financials

2026 *2027 *
Net sales - -
Net income -138M -119M -112M -102M -191M -13.07B -191M -1.33B -512M -6.69B -519M -508M -21.32B -152M -130M -123M -112M -209M -14.35B -210M -1.45B -562M -7.35B -570M -557M -23.4B
Net Debt -280M -241M -226M -207M -387M -26.47B -388M -2.68B -1.04B -13.56B -1.05B -1.03B -43.18B -404M -347M -327M -298M -558M -38.19B -559M -3.87B -1.5B -19.56B -1.52B -1.48B -62.29B
Logo Immunic, Inc.
Immunic, Inc. is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is engaged in pursuing clinical development of programs, which include the vidofludimus calcium (IMU-838) program, which is in Phase III clinical development for patients with relapsing multiple sclerosis (RMS), and which has shown therapeutic activity in Phase II clinical trials in patients suffering from relapsing-remitting MS, progressive MS and moderate-to-severe ulcerative colitis; the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, Graft-versus-Host-Disease and weight management, and the IMU-381 program, which is a molecule being developed to specifically address the needs of gastrointestinal diseases.
Employees
100
Date Price Change Volume
26-09-04 US$13.11 +2.74% 421,300
26-09-03 US$12.76 -10.39% 841,955
26-09-02 US$14.24 -2.33% 225,157
26-09-01 US$14.58 -7.72% 230,232
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.11USD
Average target price
43.09USD
Spread / Average Target
+228.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMUX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!